L-NMMA monoacetate

Grade

Highly Purified

Shipping Temp

Blue Ice

Storage Temp

-20°C

NG-Monomethyl-L-arginine . Monoacetate

Endothelium-derived relaxing factor inhibitor. Inhibits the generation of NO from arginine. Competitive, irreversible non-selective inhibitor of all three NOS I, II, and III isoforms (eNOS, iNOS and nNOS). Inhibits the synthesis of nitric oxide (NO) in a dose-dependent and enantiospecific fashion. Useful tool to study the role and the effects of NO in cardiovascular and gastrointestinal disorders, hypertension, diabetes, septic shock, inflammation, infection, stroke and neurodegenerative disorders.

Synonyms

NG-Monomethyl-L-arginine . monoacetate

CAS Number

53308-83-1

Molecular Weight

248.3

Molecular Formula

C7H16N4O2•CH3COOH

Solubility

Water, ethanol, methanol or DMSO

Appearance

Supplied as a white to off-white solid.

Purity

≥99% (TLC)

Storage and Stability

Store at 4°C. Keep cool and dry. Stable for 12 months after receipt when stored at -20°C. For maximum recovery of product, centrifuge the original vial prior to removing the cap.

Important Note

This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.

Toxicity and Hazards

All products should be handled by qualified personnel only, trained in laboratory procedures.

Form

Supplied as a white to off-white solid.

Purity

≥99% (TLC)

References

1. Identification of arginine as a precursor of endothelium-derived relaxing factor: I. Sakuma, et al.; PNAS 85: 8664 (1988) 2. NG-methylarginine, an inhibitor of endothelium-derived nitric oxide synthesis, is a potent pressor agent in the guinea pig: does nitric oxide regulate blood pressure in vivo?: K. Aisaka, et al.; BBRC 160: 881 (1989) 3. A specific inhibitor of nitric oxide formation from L-arginine attenuates endothelium-dependent relaxation: D.D. Rees, et al.; Br. J. Pharmacol. 96: 418 (1989) 4. Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo: D.D. Rees, et al.; Br. J. Pharmacol. 101: 746 (1990) 5. Role of endothelium-formed nitric oxide on vascular responses: J. Marin J & C.F. Sanchez-Ferrer; Gen. Pharmacol. 21: 575 (1990) 6. Inactivation of macrophage nitric oxide synthase activity by N(G)-methyl-L-arginine: N.M. Olken, et al.; BBRC 177: 828 (1991). 7. Nitric oxide: an endogenous modulator of leukocyte adhesion: P. Kubes, et al.; PNAS 88: 4651 (1991). 8. Macrophage nitric oxide mediates immunosuppression in infectious inflammation: T.K. Eisenstein, et al.; Immunobiology 191: 493 (1994) (Review). 9. N-nitro-L-arginine and N-monomethyl-L-arginine exhibit a differential pattern of inactivation toward the three nitric oxide synthases: D.W. Reif & C.A. McCreedy; Arch. Biochem. Biophys. 320: 170 (1995). 10. Cell death, survival and proliferation in Tetrahymena thermophila. Effects of insulin, sodium nitroprusside, 8-Bromo cyclic GMP, NG-methyl-L-arginine and methylene blue: S.T. Christensen; Cell Biol. Int. 20: 653 (1996) (Review). 11. Nitric oxide synthase inhibitors: Amino acids. O.W. Griffith & R.G. Kilbourn; Methods Enzymol. 268: 375 (1996). 12. Selective inhibitors of neuronal nitric oxide synthase-is no NOS really good NOS for the nervous system? P.K. Moore & R.L. Handy; TIPS 18: 204 (1997) (Review). 13. Asymmetric dimethylarginine (ADMA) and other endogenous nitric oxide synthase (NOS) inhibitors as an important cause of vascular insulin resistance: K. Toutouzas; Horm. Metab. Res. 40: 655 (2008) (Review). 14. Insulin resistance after hypertension induced by the nitric oxide synthesis inhibitor L-NMMA in rats: A.D. Baron; Am. J. Physiol. 269: E709 (1995). 15. The NO synthase inhibitors L-Name and L-NMMA, but not L-arginine, block the mammalian nicotinic acetyl-choline receptor channel: M Scheller; Toxicol. Lett. 100-101: 109 (1998). 16. Induction of apoptosis by L-NMMA, via FKHRL1/ROCK pathway in human gastric cancer cells: Y.Z. Wang & Z.Q. Feng; Biomed. Environ. Sci. 19: 285 (2006)